Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
12/06/13 - 06:00 AM EST
A big-money partnership with Celgene (CELG) sent OncoMed (OMED) shares sky-high in morning trading.
12/03/13 - 09:46 AM EST
- Tickers in this article:
Leukemia and Lymphoma Society has asked Stemline to stop using cancer patient testimonials in its investor presentations.
12/03/13 - 07:59 AM EST
The cash will paid to top execs if Amarin can win an expansion of its fish-oil pill.
12/03/13 - 07:45 AM EST
All things weren't equal for biopharmaceutical stocks on Monday, with Merrimack (MACK) leaping higher and Orexigen (OREX) plunging lower.
12/02/13 - 11:54 AM EST
After a weak October, biotech stocks have rebounded in a big way in November. The sector is on pace for an history year of absolute and relative performance.
12/02/13 - 07:00 AM EST
Biotech investing rarely follows a predictable script, so here's four stocks which may surprise even the most experienced investors in 2014.
11/27/13 - 07:00 AM EST
After a red-hot start, biotech IPOs are now underperforming the broader market.
11/26/13 - 09:42 AM EST
This red-hot biotech could double again.
11/26/13 - 06:30 AM EST
Orexigen Therapeutics is the best-performing obesity drug stock of 2013, topping rivals Vivus and Arena Pharma.
11/25/13 - 12:10 PM EST
Stocks are responding to the deal with Iran, as Orexigen clears safety hurdle for its obesity drug Contrave. Adam Feuerstein gives details.
11/25/13 - 11:17 AM EST
Biogen Idec and Gilead Sciences are helping the biotech sector recover from a sloppy fourth quarter performance.
11/22/13 - 12:52 PM EST